Introduction
Until just a few years ago, management of most lysosomal storage diseases (LSDs) consisted only of supportive care. Nowadays, different treatment options are available for an extending list of LSDs including enzyme replacement therapy, substrate reduction with iminosugar, chaperones and hematopoietic cell transplantation (HSCT). [1] [2] [3] The results achieved by HSCT in some disorders proved that donor-derived macrophages and microglia can progressively become a stable source of endogenous enzyme crosscorrecting defective cells in the central nervous system (CNS). However, the correct place for transplant procedures in LSDs needs constant redesigning, as with the exception of mucopolysaccharidosis type I-H, [4] [5] [6] efficacy is still not yet well defined, problematic and challenging.
Results have been unsatisfactory in many disorders, particularly in some leukodystrophies such as metachromatic leukodystrophy (MLD), outlining the need for testing innovative emerging therapeutic approaches.
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The disease MLD is an autosomal-recessive inherited lysosomal disorder, characterized by the deficiency of the enzyme arylsulfatase-A (ARSA), or, more rarely, of its activator protein saposin-B. [13] [14] [15] Partial deficiency of this enzyme is also found in non-affected individuals, a condition for which the term pseudodeficiency was introduced. ARSA is involved in sulfatide metabolism through the hydrolysis of the 3-O ester bond of galactosyl and lactosyl sulfatides. Its deficiency leads to the accumulation of these substrates in metachromatic granules in oligodendrocytes, macrophages and some subtypes of neurons in the CNS, in Schwann cells and macrophages in the peripheral nervous system (PNS), and in visceral organs such as kidney, liver, gallbladder, pancreas, testes, sweat glands, adrenal cortex and rectal tissue. The human gene for ARSA maps to the long arm of chromosome 22 is 3.2 kb long, and consists of eight exons. More than 100 MLD-related ARSA mutations have been described to date, with the frequency differing among ethnic groups. Nevertheless, roughly 50% of the MLD alleles remain unidentified. MLD mutations can be functionally divided into two broad groups: 0 alleles associated with no enzymatic activity and R alleles encoding for ARSA with minimal residual enzymatic activity. The 0 allele 459 þ 1G4A, and the R alleles 1277C4T and 536T4G represent the most frequent mutations encountered in the European population. [16] [17] [18] [19] The available epidemiological data are scarce, but all sources indicate that MLD is an extremely rare disorder with an incidence of 0.06-0.25 in 10 000. More recent reports estimated the birth prevalence of MLD to be 1.4-1.8 per 100 000 for all types combined. 20, 21 The specific diagnosis depends on a combination of biochemical procedures and mutation analysis. [22] [23] [24] However, biochemical analysis may be misleading because of the considerable variability in enzyme activities among individuals; the measurable ARSA activity in cultured fibroblasts varies with culture conditions, and the presence of the pseudodeficient allele, which accounts for 5-15% of residual activity, could lead to an incorrect diagnosis or assignment of carrier status. Distinction between the different possible conditions requires the analysis of sulfatides in a 24-h urine collection and molecular analysis. Urinary sulfatide excretion is increased in patients with MLD but normal or only minimally increased in patients with pseudodeficiency. Normal ARSA activity is observed in MLD patients with saposin-B deficiency because the colorimetric assay used for determining ARSA activity is not affected by activator defects. In these patients, sulfatiduria is positive. Mutation analysis provides an increasingly important diagnostic tool. 25 As the three most common mutations screened on a routine basis (459 þ 1G4A, P426L and I179S) are present in less than 50% of the patients, sequencing of the entire coding region of the ARSA gene is often needed.
Other diagnostic tools include brain nuclear magnetic resonance and electroneurographic recordings. Brain magnetic resonance shows a diffuse symmetric hyperintense signal in both the periventricular and subcortical supratentorial white matter on FLAIR (fluid-attenuated inversion recovery) and T2-weighted images. As the disease progresses, other structures are involved, such as corpus callosum, cerebellar white matter, corticospinal tracts, internal capsules and thalami. In the late stages, the U-fibers are involved and atrophy appears. Another common finding is the tigroid pattern of demyelination. The lesions do not enhance. Peripheral neuropathy is constantly present with early onset forms in MLD patients in whom it manifests as a demyelinating neuropathy with progressive and severe reduction of nerve conduction velocities. It has also been reported, albeit less severely, in late onset patients.
The disease is usually classified into four main different variants according to the age at onset: late infantile, early juvenile and late juvenile, and adult forms. The late infantile form usually manifests in the second year of life. The juvenile variant, with an onset between 4 and 15 years, is further subdivided into early juvenile and late juvenile depending on whether the onset is before or after 6 years of age. Patients with onset between 2 and 4 years are not yet well characterized, but the tendency is to consider these patients as belonging to the juvenile onset group, with a very early onset. Adult forms refers to the variant with onset after early teens. Clinical manifestations, because of the involvement of the CNS and PNS, and disease progression vary among the different forms. Late infantile and early juvenile cases are the most frequent, having a more severe phenotype and rapid progression. They are characterized by signs and symptoms of involvement of both CNS and PNS, such as developmental delay or psychomotor regression, ataxia, progressive spastic quadriparesis, dysphagia, blindness and deafness, seizures, diffuse atrophy and weakness with areflexia. Prognosis is severe, leading to death a few years after the onset of symptoms. There is a considerable heterogeneity within the clinical variants with respect to the onset, clinical course and progression. In late juvenile cases, cognitive difficulties generally precede gait disturbances and the progression is slower. In the adult form, behavioral and intellectual changes are often the presenting symptoms, followed by spastic paraparesis and incontinence. 14, 26 Treatment Currently, no available treatment can reverse the fatal outcome of this devastating disease, and therapy is only supportive. Various dietary regimens and pharmacological agents have not had a favorable effect on the clinical course or biochemical abnormalities. HSCT proved to be ineffective in children with the late infantile disease and generally in all patients with evident neuropsychological and/or neurological signs. 3, 7 Enzyme replacement therapy has very recently entered clinical testing and although efficacy data are still pending, it is affected by significant limitations. In fact, the blood-brain barrier is a major obstacle for systemically administered therapeutic molecules to reach the brain, and lifelong administration is required. The severity of the disease and the absence of effective therapies outline the need for testing innovative therapeutic approaches. Gene therapy strategies could represent a significant advance when compared with conventional allogeneic HSCT. Autologous hematopoietic cells may be genetically modified to constitutively express supra-normal levels of the therapeutic enzyme and become a quantitatively more effective source of functional enzyme than normal donor cells. Moreover, autologous transplantation is associated with a significantly reduced transplant-related morbidity and TRM, and avoids the risks of GVHD.
Hematopoietic cell transplantation
Over the past three decades, approximately 1000 HSCTs have been performed worldwide for patients with a wide range of different LSDs. The aim of HSCT is to repopulate recipient hematopoietic and lymphoid compartments with cells expressing a functional hydrolase. Macrophages and microglia represent major effectors of the catabolism of the storage material, and their replacement by normal cells also has the potential to restore a critical scavenger function. From the impressive results in Hurler syndrome, it was expected that most storage disorders could be alleviated by HSCT. However, along the way, benefit from HSCT appeared to be limited only to selected subsets of patients affected by a small number of LSDs. HSCT proved ineffective in patients with overt neurological symptoms or in those with early onset or aggressive infantile forms. The main reason for HSCT failure is the slow pace of replacement of resident tissue macrophages/histiocytes and microglia populations by the transplanted hematopoietic cell progeny as compared with the rapid progression of the primary disease. This lag period which is expected to be in the range of 12-24 months before initial disease stabilization, makes it necessary to extrapolate the likely condition of the patient at that future stage before deciding eligibility to transplantation: the more severe the phenotype and the longer the interval from onset of first obvious symptoms to HSCT, the poorer the outcome. Furthermore, an additional great challenge in this area of transplantation remains the high frequency of primary and secondary graft failures and incomplete donor chimerism. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Even though more than 100 HSCTs have performed for MLD worldwide, information gathered from the literature is limited, probably because the experience was poor. Data collection for this disease has never become as routine as for patients undergoing HSCT for malignancies or, more recently, for other LSDs. Only a minority of the transplanted MLD cases has been published and the same patients have been repeatedly reported in small series or as single case reports; most frequently, the post-transplant follow-up is short and does not allow proper interpretation of the clinical outcome of the procedure. Furthermore, the reported positive outcome of the patient does not frequently correspond to the primary goal of HSCT, which is not simply promoting long-term patient survival with donor engraftment, but switching the patient's phenotype to a less severe one compatible with the family and patient's concept of an acceptable quality of life. 3 Late infantile MLD cannot be effectively treated by HSCT of any type, cord blood or BM. 3, 7, [27] [28] [29] The claim that late infantile MLD patients transplanted when asymptomatic (and at least 1 year before the age of onset in the affected sibling) remain asymptomatic has never been proven. The reported course, following HSCT, in juvenile/ adult forms appears to be often comparable with the natural course of the expected disease, which is usually characterized by a slow progression of symptoms. [30] [31] [32] [33] [34] [35] Despite full engraftment and normalcy of enzymatic activity, in these forms the only benefit might be an improved survival in selected cases, whereas failure to obtain an improved or stabilized quality of life appears common. 27, 28, 36 Recent clinical evidence obtained in patients affected by globoid cell leukodystrophy, an LSD related to MLD and consequent to the deficiency of the enzyme involved in the downstream reaction, following ARSA, in the catabolism of myelin lipids, indicate that cord blood transplantation may favorably alter the natural history of infantile forms by delaying onset and progression if performed in asymptomatic newborns at less than 4 weeks of age. 37 Most patients have outlived their untreated affected siblings, but it has been reported recently that the vast majority of them at 2 years of age demonstrated varying degrees of spasticity (i.e., unable to walk without assistance). 9 The same studies confirmed that HSCT did not result in any substantial neurological benefit if performed in babies aged 44 months at transplant. According to the results achieved in globoid cell leukodystrophy, cord blood transplantation might be tested, within the first 2-4 weeks of life following prenatal diagnosis, in newborns with MLD and some cases have already been reported. 38, 39 However, following a first affected child in a family, the recommended practice of prenatal diagnosis for subsequent siblings makes the identification of a cohort of affected newborns eligible to such a study unlikely.
Perspectives on treatment
Enzyme replacement therapy Because of its potential to compensate the deficiency, enzyme replacement therapy has become the most promising therapeutic option for various LSDs and it is currently available as treatment for some disorders (Fabry, Gaucher, Pompe, mucopolysaccharidosis I, II and VI) or is under development for others such as MLD. 40 A Phase I-II enzyme replacement therapy trial is ongoing to evaluate the safety, efficacy and pharmacokinetics of the rhARSA administration in patients with late infantile MLD. However, protein delivery poses serious challenges when sustained administration is required and when CNS and PNS are the major disease targets, as in the case of MLD. In fact, the blood-brain barrier severely limits access of systemically administered therapeutic molecules to the nervous tissue, greatly reducing the therapeutic impact of this strategy. Furthermore, recurring parenteral administration of an exogenous protein carries the risk of inducing an immune response against the therapeutic enzyme, thus reducing the overall therapeutic impact of the treatment.
Gene therapy HSC gene therapy has long been considered an attractive option for the treatment of LSDs. Autologous HSC gene therapy may be able to: (i) repopulate affected tissues with donor-derived myeloid cells, including CNS microglia, which then become an effective tissue source of the functional enzyme; (ii) further improve the therapeutic potential of HSCT, upon genetic modification of autologous cells, to become a quantitatively more effective enzymatic source than normal donor cells by constitutive expression at supra-physiological levels of the functional enzyme; (iii) reduce allogeneic HSCT side effects, as the autologous procedure is associated to a reduced transplantrelated morbidity and TRM, and avoids the risks of GVHD. The therapeutic efficacy of HSC gene therapy in controlling disease manifestations has been shown in preclinical models of MLD. 41, 42 These studies highlighted the requirement of unexpectedly high levels of ARSA for the correction of the metabolic defect in the MLD CNS. This requirement can be met only upon high-frequency HSC transduction and robust therapeutic gene expression in their progeny. Lentiviral vectors (LV) enable efficient gene marking of mouse and human HSC with minimal in vitro manipulation and cell perturbation, allowing for full maintenance of stem cell properties, and robust long-term transgene expression in the HSC differentiated progeny. 43 Thus, LV provide the opportunity of achieving high enzyme expression levels in affected tissues. Remarkably, HSC gene therapy with LV allowed prevention and correction of MLD manifestations in the mouse model, and had a significantly better therapeutic impact than wildtype HSC transplantation. 41, 42 Indeed, our preclinical work has demonstrated that the unique advantage of gene therapy over conventional HSCT is because of the expression of the functional enzyme in HSC and in their progeny greatly above normal donor levels, which allows for the halting of disease progression. The fundamental issues related to the safety of LV-mediated ARSA overexpression in HSC and their progeny, and to that of LV integration into the HSC genome have been addressed in adequate animal models, providing further support for future clinical testing of this strategy. 44, 45 On the basis of this evidence, a Phase I/II gene therapy clinical trial is in the final process of being reviewed and approved and will be opened for enrollment at the beginning of the next year. The 'medicinal product' ('autologous CD34 þ cells transfected with lentiviral vector containing the human ARSA cDNA for treatment of MLD') has already been granted by the European Commission for Orphan Drug Designation (EMEA/ COMP 84536/2007).
Conclusions
MLD is a devastating and fatal disease. After nearly 30 years of transplant activity for this disorder, there is enough evidence to conclude that in general HSCT should be contraindicated for MLD, unless performed under specifically approved clinical research trials for a very limited subset of patients (newborns). An effort from the scientific community should be made to collect data with the aim of transforming such a statement into a practiced recommendation. The severity of the disease and the absence of effective therapies highlight the need for testing innovative therapeutic approaches such as enzyme replacement and gene therapy. Genetically modified autologous hematopoietic stem/progenitor cells can constitutively express supra-physiological levels of ARSA becoming a quantitatively more effective source of functional enzyme when transplanted in patients with MLD. This innovative approach might overcome the limits of 'conventional' HSCT.
